Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
The National Association of Attorneys General has submitted a letter to the U.S. Food and Drug Administration, signed by a ...
8h
HealthDay on MSNWeight-Loss Drugs Could Help Extend Life of Replacement JointsEven slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearin ...
When Trova Wine and Market in Dallas shut its doors last month after nearly five years in business, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like ...
1h
24/7 Wall St. on MSNHIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDA ...
We speak to Kerry North America CEO John Cahalane to find out more about the company’s renewed strategy at a time when consumer focus on health and nutrition is reaching a new high ...
Lexaria Bioscience Corp.: Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results